– June 1, 2013
June 1, 2013
View Archives Issues
-
Single-Dose Fosaprepitant
Current strategies to prevent chemotherapy-induced nausea and vomiting frequently include a 3-day course of aprepitant. In a multicenter trial from Japan, administration of a single dose of the aprepitant prodrug fosaprepitant, when used in combination with granisetron and dexamethasone, was shown to provide significant improvement when compared to placebo plus granisetron/dexamethasone. Thus, single-dose fosaprepitant may offer a more convenient and less complicated approach in the regimen to prevent nausea and vomiting. -
Does Delaying Adjuvant Chemotherapy for Non-small Cell Lung Cancer Affect Survival?
One-third of non-small cell lung cancer patients treated with adjuvant chemotherapy start it more than 10 weeks after surgery. Although the time interval between surgery and initiation of adjuvant chemotherapy impacts survival in colorectal and breast cancers, delaying adjuvant chemotherapy does not appear to be associated with inferior survival in non-small cell lung cancer. -
Adjuvant Chemotherapy for Elderly Stage III Colon Cancer Patients
In a retrospective review of adjuvant chemotherapy for elderly (≥ 75 years) patients with stage III colon cancer, performance status and comorbidities were important treatment decision factors. Disease recurrence rates were not different for those who received adjuvant treatment vs those who did not, but 1-year and 5-year survival was significantly better for the treated group. The difference at 5 years remained apparent in multivariate analysis controlling for age, performance status, and comorbidities. -
Plasma EBV Levels as a Prognostic Marker in Patients with Advanced Hodgkin Lymphoma
In this study, the authors studied the prognostic value of plasma Epstein Barr virus (EBV) DNA levels at diagnosis and 6 months post-treatment in patients with advanced Hodgkin lymphoma treated on the North American Cooperative Intergroup Trial E2496. -
The Right Care, the Right Time, the Right Doc: Only Part of the Story...
Clinically significant disparities exist in the quality of ovarian cancer care delivered and in overall survival along both racial and socioeconomic status. These effects appear to persist despite adherence to National Comprehensive Cancer Network guidelines; however, deviation in guideline adherence is common and further impacts survivorship and represents key opportunities for further investigation and study. -
Pharmacology Watch: Do Perioperative Beta-Blockers Reduce Mortality?
Beta-blockers and noncardiac surgery; prenatal medication exposure and risk of autism; reasons for statin discontinuations; and FDA actions. -
Clinical Briefs in Primary Care Supplement